Combination of Ibrutinib and Nivolumab Overcomes Ibrutinib Resistance in a Novel Patient-Derived Mantle Cell Lymphoma 3D Model
Ferran Araujo‐Ayala(Fundació Clínic per a la Recerca Biomèdica), Patricia Pérez‐Galán(Centro de Investigación Biomédica en Red de Cáncer), Armando López‐Guillermo(Barcelona Supercomputing Center), Rubén Giménez(Centro de Investigación Biomédica en Red de Cáncer), Carla Faria(Inserm), Elı́as Campo(Hospital Clínic de Barcelona), Heribert Playà-Albinyana(Centro de Investigación Biomédica en Red de Cáncer), Christine Bezombes(Centre National de la Recherche Scientifique), Fabien Gava, Eva Giné(Aristotle University of Thessaloniki), Ferran Nadeu(Centro de Investigación Biomédica en Red de Cáncer), Pascale Bernes-Lasserre, Neus Serrat(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Marine Norlund, Dolors Colomer(Hospital Clínic de Barcelona), Cèlia Dobaño‐López(Centro de Investigación Biomédica en Red de Cáncer), Juan García Valero(Université Claude Bernard Lyon 1), Jean Michel Lagarde(Sorbonne Université), Renaud Morin
Cited by 1
Related Papers
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
|Blood|2011|2k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k